Back to Search
RANDOLPH GEARY, MD
MD
Vascular Surgery Physician
NPI: 1245215300Individual
Specialties, Licenses & Credentials
Surgery Physician
Surgery
Code: 208600000X
9400504(NC)
Surgical Critical Care Physician
Surgery — Surgical Critical Care
Code: 2086S0102X
9400504(NC)
Vascular Surgery PhysicianPrimary
Surgery — Vascular Surgery
Code: 2086S0129X
9400504(NC)
Research & Publications (20)
Antisense oligonucleotide pharmacokinetics and metabolism.
PMID 19379126·Expert Opin Drug Metab Toxicol·2009
6-review
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.
PMID 19393225·Biochem Pharmacol·2009
7-preclinical
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
PMID 16884318·Clin Pharmacokinet·2006
3-trial
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
PMID 14570775·Drug Metab Dispos·2003
4-observational
Expression profiling identifies 147 genes contributing to a unique primate neointimal smooth muscle cell phenotype.
PMID 12482827·Arterioscler Thromb Vasc Biol·2002
4-observational
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
PMID 11566019·Curr Opin Investig Drugs·2001
7-preclinical
Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
PMID 11181921·J Pharmacol Exp Ther·2001
7-preclinical
Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
PMID 11181922·J Pharmacol Exp Ther·2001
7-preclinical
Restenosis after renal artery angioplasty and stenting: incidence and risk factors.
PMID 19595532·J Vasc Surg·2009
8-other
The in vivo stability of electrospun polycaprolactone-collagen scaffolds in vascular reconstruction.
PMID 18990437·Biomaterials·2009
7-preclinical
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
PMID 19056355·Biochem Pharmacol·2009
4-observational
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
PMID 19071883·Clin Pharmacokinet·2009
3-trial
Efficient recovery of endothelial progenitors for clinical translation.
PMID 19125587·Tissue Eng Part C Methods·2009
7-preclinical
RGS5, RGS4, and RGS2 expression and aortic contractibility are dynamically co-regulated during aortic banding-induced hypertrophy.
PMID 18207159·J Mol Cell Cardiol·2008
7-preclinical
Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength.
PMID 18337405·J Neurosci·2008
4-observational
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
PMID 17172312·Drug Metab Dispos·2007
3-trial
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.
PMID 17332893·J Clin Invest·2007
8-other
Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice.
PMID 17389243·J Pharmacol Exp Ther·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- MEDICAL CENTER BLVD
WINSTON SALEM, NC 27157 - Phone
- (336) 716-2255
Quick Facts
- NPI
- 1245215300
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile